Yinao Capsules Combined with Memantine Hydrochloride in the Treatment of Alzheimer’s Disease in the Elderly

Objective: To investigate the clinical efficacy of Yinao capsule combined with memantine hydrochloride in the treatment of Alzheimer’s disease (AD) in the elderly, and to analyze its effects on cognitive function and quality of life of patients. Methods: A total of 84 elderly AD patients admitted to the hospital from June 2022 to June 2023 were randomly divided into an observation group (42 cases, Yinao capsule combined with memantine hydrochloride) and a control group (42 cases, memantine hydrochloride monotherapy), both of which were treated for 3 months. The Mini-Intelligent Mental State Scale (MMSE) was used to evaluate cognitive function, and the Quality of Life Scale for Alzheimer’s Patients (QOL-AD) was used to evaluate the quality of life. Results: Before treatment, there was no significant difference in the MMSE AND QOL-AD scores between the two groups (P>0.05).  After 3 months of treatment, the MMSE AND QOL-AD scores of both groups were significantly higher than those before treatment (both P<0.001), and the MMSE (24.70±3.70 points) and QOL-AD (31.60±3.59 points) scores in the observation group were significantly higher than those in the control group (21.24±3.33 points) and (28.44±3.26 points), both P<0.001. There were no serious adverse reactions in either group. Conclusion: Yinao capsule combined with memantine hydrochloride can significantly improve cognitive function and quality of life in elderly AD patients, and the efficacy is better than memantine hydrochloride monotherapy, and the safety is good.